GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q1 FY23 results · Apr–Jun 2022
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹745.10 crore (down 5.7% from Q1 FY22) and net profit of ₹119.28 crore (down 1.5% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 745.10 | 789.99 | −5.7% | 809.63 | −8.0% |
| Other income | 27.61 | 31.73 | −13.0% | 18.76 | +47.2% |
| Total income | 772.71 | 821.72 | −6.0% | 828.39 | −6.7% |
| Profit before tax | 160.03 | 164.90 | −3.0% | 207.85 | −23.0% |
| Net profit for the period | 119.28 | 121.08 | −1.5% | 1,219.05 | −90.2% |
| EPS, basic (₹) | 7.04 | 7.15 | −1.5% | 71.96 | −90.2% |
| Net margin (%) | 16.0 | 15.3 | 150.6 |
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 729.46 | 773.46 | −5.7% | 791.92 | −7.9% |
| Other income | 27.79 | 31.73 | −12.4% | 18.94 | +46.7% |
| Total income | 757.25 | 805.19 | −6.0% | 810.86 | −6.6% |
| Profit before tax | 159.22 | 163.92 | −2.9% | 206.24 | −22.8% |
| Net profit for the period | 118.68 | 120.40 | −1.4% | 1,217.84 | −90.3% |
| EPS, basic (₹) | 7.01 | 7.11 | −1.4% | 71.89 | −90.2% |
| Net margin (%) | 16.3 | 15.6 | 153.8 |
Consolidated
- Filed with BSE
- 26 Jul 2022, 11:30 IST
- Board meeting
- 25 Jul 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 26 Jul 2022, 11:30 IST
- Board meeting
- 25 Jul 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE